Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is aserious, chronic, and progressivedisease that is rapidly increasing in prevalence. The disease now affects.10 % of adults in some developed coun-tries, increasing most in Asia. People with T2DM are two to four times more likely to develop a serious cardiovascular (CV) outcome compared with those without diabetes. The majority of patients with T2DM are insulin resistant and have asso-ciated metabolic abnormalities that are themselves significant CV risk factors. It is believed that most of this increased risk is caused by lipid abnormalities, hyper-tension, chronic vascular inflammation, and a proatherothrombotic state. The glycemia-related contribution is evidently
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874 · cited 1×
“There is epidemiological evidence suggesting that achieving low HbA1c with insulin-based regimens or a sulfonylurea-metformin combination therapy increases the risk of all-cause mortality and CV events (19).”
BackgroundSelf-citationPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 1×
“In addition to providing sustained glycemic control in T2DM patients, pioglitazone resulted in a 70% reduction in the risk of developing T2DM in the Actos Now for the prevention of diabetes (ACT NOW) study (6).”
BackgroundRisk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444 · cited 1×
“(29) reported the risk of incident MI, congestive heart failure (CHF), and all-cause mortality in relation to oral antidiabetes drugs in 91,521 people with diabetes (mean follow-up per individual: 7.”
BackgroundNatali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284 · cited 2×
“In the French study (49), the reported HR was 1.”
BackgroundDoehner, W., Erdmann, E., Cairns, R., Clark, A. L., Dormandy, J. A., Ferrannini, E., & Anker, S. D. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.039 · Cited by 215 · cited 1×
“6 kg in the PROactive study (21), but interestingly, weight gain rather than weight loss was associated with an improved survival in patients treated with pioglitazone in a post hoc analysis of the PROactive population (34).”
BackgroundKung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Charbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1751-1 · Cited by 170 · cited 2×
“Effects of pioglitazone on microalbuminuria and outcome in T2DM patients with chronic kidney disease In the QUARTET studies, a consistent lowering effect of pioglitazone on microalbuminuria (estimated as albumin-tocreatinine ratio) was evident, which was not seen with metformin or sulfonylureas (2,3).”
BackgroundResultSelf-citationLincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group (2013) · Diabetes Care · doi:10.2337/dc11-2197 · Cited by 37
Cited by
The role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Diagnosing and managing diabetes in HIV-infected patients: current concepts
Monroe, A. K., Glesby, M. J., & Brown, T. T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu779 · Cited by 125
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Metadata
- Authors
- Schernthaner, G., Currie, C. J., & Schernthaner, G.-H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S155-S161
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2119214646
- Cited by
- 100
- References
- 15
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.